Matthew J. Brady to Insulin Receptor Substrate Proteins
This is a "connection" page, showing publications Matthew J. Brady has written about Insulin Receptor Substrate Proteins.
Connection Strength
0.508
-
The novel endocrine disruptor tolylfluanid impairs insulin signaling in primary rodent and human adipocytes through a reduction in insulin receptor substrate-1 levels. Biochim Biophys Acta. 2012 Jun; 1822(6):952-60.
Score: 0.418
-
IRS2 takes center stage in the development of type 2 diabetes. J Clin Invest. 2004 Oct; 114(7):886-8.
Score: 0.063
-
The endocrine disrupting chemical tolylfluanid alters adipocyte metabolism via glucocorticoid receptor activation. Mol Endocrinol. 2013 Mar; 27(3):394-406.
Score: 0.028